EMA Application withdrawn: Flynpovi (eflornithine hydrochloride;sulindac) — Cancer Prevention Pharma (Ireland) Limited

View source ↗

Summary

EMA withdrew the application for Flynpovi (eflornithine hydrochloride; sulindac) for Adenomatous Polyposis Coli.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenomatous Polyposis Coli

Drugs mentioned

• Flynpovi (eflornithine hydrochloride; sulindac)

Snippet

Status: Application withdrawn. Therapeutic area: Adenomatous Polyposis Coli. MAH: Cancer Prevention Pharma (Ireland) Limited. Orphan medicine